OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
EVAX$4.1258

Evaxion A/S

Biotechnology & Medical ResearchVerified

Evaxion maintains a capital structure with no debt, as indicated by a debt-to-equity ratio of 0.0, and a total equity of $2.6 million. The company's liquidity position is unclear due to the absence of balance-sheet inputs and no going-concern language in source documents. The market capitalization of $34.4 million suggests a small-cap profile, with a price-to-earnings ratio of 28.78, indicating a premium valuation relative to earnings. The company's profitability is mixed, with a net income of $1.2 million but an operating loss of $4.4 million. The return on equity of 45.85% is strong, but this is likely driven by the low equity base rather than operational efficiency. The company's performance is not benchmarked against industry medians due to the lack of industry-specific metrics in the provided data. Evaxion's revenue is concentrated in a single business segment, as disclosed in the financial snapshot, with no geographic breakdown provided. The absence of segment or geographic data limits the ability to assess diversification risks or growth opportunities in different markets. The company's growth trajectory is uncertain, with no specific revenue growth rates or outlooks provided in the data. Analysts have assigned a mean price target of $11.25, with a median of $10.00, suggesting a potential upside from the current market price of $4.12. However, the lack of detailed revenue history and forward-looking guidance makes it difficult to assess the sustainability of this growth. Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and the absence of going-concern language. The dilution risk is currently low, but the company may face pressure to raise additional capital if it continues to operate at a loss. No specific dilution sources are identified in the data, and the probability of near-term dilution remains low. Recent events and filings are not detailed in the provided data, so no specific recent developments can be reported. The company's financial statements and analyst estimates are the primary sources of information, with no additional transcripts or filings referenced.

30-day price · EVAX(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyEvaxion A/S
TickerEVAX.O
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Evaxion A/S is a biotechnology company focused on healthcare diagnostics, developing and commercializing AI-driven vaccine and drug discovery platforms.

Classification. Evaxion is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a confidence level of 0.92.

Evaxion maintains a capital structure with no debt, as indicated by a debt-to-equity ratio of 0.0, and a total equity of $2.6 million. The company's liquidity position is unclear due to the absence of balance-sheet inputs and no going-concern language in source documents. The market capitalization of $34.4 million suggests a small-cap profile, with a price-to-earnings ratio of 28.78, indicating a premium valuation relative to earnings. The company's profitability is mixed, with a net income of $1.2 million but an operating loss of $4.4 million. The return on equity of 45.85% is strong, but this is likely driven by the low equity base rather than operational efficiency. The company's performance is not benchmarked against industry medians due to the lack of industry-specific metrics in the provided data. Evaxion's revenue is concentrated in a single business segment, as disclosed in the financial snapshot, with no geographic breakdown provided. The absence of segment or geographic data limits the ability to assess diversification risks or growth opportunities in different markets. The company's growth trajectory is uncertain, with no specific revenue growth rates or outlooks provided in the data. Analysts have assigned a mean price target of $11.25, with a median of $10.00, suggesting a potential upside from the current market price of $4.12. However, the lack of detailed revenue history and forward-looking guidance makes it difficult to assess the sustainability of this growth. Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and the absence of going-concern language. The dilution risk is currently low, but the company may face pressure to raise additional capital if it continues to operate at a loss. No specific dilution sources are identified in the data, and the probability of near-term dilution remains low. Recent events and filings are not detailed in the provided data, so no specific recent developments can be reported. The company's financial statements and analyst estimates are the primary sources of information, with no additional transcripts or filings referenced.
Key takeaways
  • Evaxion is a biotechnology company with a focus on healthcare diagnostics and AI-driven drug discovery.
  • The company has a strong return on equity but operates at a significant operating loss.
  • The company's capital structure is entirely equity-based, with no debt.
  • Analysts have assigned a mean price target of $11.25, indicating potential upside from the current market price.
  • The company's liquidity risk cannot be assessed due to missing balance-sheet data.
  • The company's growth trajectory is uncertain, with no detailed revenue history or forward-looking guidance provided.
  • --
  • # RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$51.0k
Gross profit
Operating income-$4.4M
Net income$1.2M
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities$20.1M
Total equity$2.6M
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4-$25.8M-$24.5M-$25.5M
FY-3-$25.3M-$23.2M-$22.8M
FY-2$73.0k-$22.2M-$22.1M-$21.6M
FY-1$3.3M-$14.7M-$10.6M-$10.0M
FY0$7.5M-$6.7M-$7.7M-$7.1M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$40.2M$32.4M
FY-3$22.0M$8.3M
FY-2$12.9M-$4.7M
FY-1$12.5M-$1.7M
FY0$28.4M$17.0M
PeriodOCFCapExFCFSBC
FY-4-$21.9M-$1.4M-$25.5M
FY-3-$25.8M-$292.0k-$22.8M
FY-2-$17.7M-$87.0k-$21.6M
FY-1-$12.9M$0.00-$10.0M
FY0-$6.6M-$11.0k-$7.1M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$51.0k-$4.4M$1.2M
FQ-6$154.0k-$4.6M-$6.2M
FQ-5$3.0M-$1.7M-$1.9M
FQ-4$122.0k-$4.0M-$3.6M
FQ-3$0.00-$3.9M-$1.6M
FQ-2$37.0k-$4.3M-$4.8M
FQ-1$7.5M$3.0M$4.6M
FQ0$0.00-$1.5M-$5.9M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$2.6M
FQ-6$15.2M$1.3M
FQ-5$74.0k
FQ-4$12.5M-$1.7M
FQ-3$10.3M
FQ-2$22.4M$6.2M
FQ-1
FQ0$28.4M$17.0M
PeriodOCFCapExFCFSBC
FQ-7
FQ-6-$9.0M$0.00
FQ-5
FQ-4-$12.9M$0.00
FQ-3
FQ-2-$7.7M
FQ-1
FQ0-$6.6M-$11.0k
Valuation
Market price$4.12
Market cap$34.4M
Enterprise value
P/E28.8
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity0.0
ROA
ROE45.9%
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 170 companies
MetricEVAXActivity
Op margin-8619.6%-227.5% medp25 -1250.6% · p75 -3.5%bottom quartile
Net margin2341.2%-194.5% medp25 -1233.8% · p75 0.8%top quartile
Gross margin53.0% medp25 25.9% · p75 75.7%
CapEx / revenue-8.2% medp25 -35.2% · p75 -2.5%
Debt / equity0.0%1.2% medp25 0.0% · p75 17.4%bottom quartile
Observations
IR observations
Mean price target11.25 USD
Median price target10.00 USD
High price target16.00 USD
Low price target9.00 USD
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count4.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-1.17 USD
Last actual EPS-1.00 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-16 22:13 UTC#6276728c
Market quoteclose USD 4.41 · shares 0.01B diluted
no public URL
2026-05-16 22:13 UTC#de2631b9
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 21:56 UTCJob: 48531470